301 related articles for article (PubMed ID: 29357824)
21. Pazopanib and soft-tissue sarcomas. Too toxic.
Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Bupathi M; Hays JL; Chen JL
PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
[TBL] [Abstract][Full Text] [Related]
24. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
Karaağaç M; Eryılmaz MK
J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
[TBL] [Abstract][Full Text] [Related]
25. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor.
Lee CH; Mariño-Enriquez A; Ou W; Zhu M; Ali RH; Chiang S; Amant F; Gilks CB; van de Rijn M; Oliva E; Debiec-Rychter M; Dal Cin P; Fletcher JA; Nucci MR
Am J Surg Pathol; 2012 May; 36(5):641-53. PubMed ID: 22456610
[TBL] [Abstract][Full Text] [Related]
26. Response to Pazopanib in Patients With Relapsed Osteosarcoma.
Elete KR; Albritton KH; Akers LJ; Basha R; Ray A
J Pediatr Hematol Oncol; 2020 May; 42(4):e254-e257. PubMed ID: 30531600
[TBL] [Abstract][Full Text] [Related]
27. First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.
Buti S; Bersanelli M; Maines F; Facchini G; Gelsomino F; Zustovich F; Santoni M; Verri E; De Giorgi U; Masini C; Morelli F; Vitale MG; Sava T; Prati G; Librici C; Fraccon AP; Fornarini G; Maruzzo M; Leonardi F; Caffo O
Clin Genitourin Cancer; 2017 Aug; 15(4):e609-e614. PubMed ID: 28108284
[TBL] [Abstract][Full Text] [Related]
28. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
29. YWHAE-NUTM2A/B Translocated High-grade Endometrial Stromal Sarcoma Commonly Expresses CD56 and CD99.
McCluggage WG; Lee CH
Int J Gynecol Pathol; 2019 Nov; 38(6):528-532. PubMed ID: 30252726
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
32. Megestrol acetate therapy for advanced low-grade endometrial stromal sarcoma.
Lim MC; Lee S; Seo SS
Onkologie; 2010; 33(5):260-2. PubMed ID: 20502061
[TBL] [Abstract][Full Text] [Related]
33. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.
Westerdijk K; Krens SD; Steeghs N; van der Graaf WTA; Tjwa ETTL; Westdorp H; Desar IME; van Erp NP
Cancer Chemother Pharmacol; 2024 Apr; 93(4):353-364. PubMed ID: 38104304
[TBL] [Abstract][Full Text] [Related]
34. Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report.
Akashi D; Todo Y; Shimada C; Okamoto K; Minobe S; Kato H
Jpn J Clin Oncol; 2013 Nov; 43(11):1145-9. PubMed ID: 24058200
[TBL] [Abstract][Full Text] [Related]
35. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
[TBL] [Abstract][Full Text] [Related]
36. Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan.
Teshima Y; Nomura S; Fukasawa N
Jpn J Clin Oncol; 2021 Apr; 51(4):612-621. PubMed ID: 33283234
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
38. A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
Salvatierra A; Tarrats A; Gomez C; Sastre JM; Balaña C
Gynecol Oncol; 2006 Jun; 101(3):545-7. PubMed ID: 16487996
[TBL] [Abstract][Full Text] [Related]
39. Total Pelvic Exenteration for Recurrent Endometrial Sarcoma - A Case Report.
Suciu N; Bălescu I; Bacalbaşa N
Chirurgia (Bucur); 2015; 110(5):486-9. PubMed ID: 26531797
[TBL] [Abstract][Full Text] [Related]
40. Surgical cytoreduction and hormone therapy of an advanced endometrial stromal sarcoma of the ovary.
Geas FL; Tewari DS; Rutgers JK; Tewari KS; Berman ML
Obstet Gynecol; 2004 May; 103(5 Pt 2):1051-4. PubMed ID: 15121605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
